date:Apr 23, 2012
ould face antitrust issues and may have to sell portions of the unit in Latin America, Southeast Asia and South Africa. However, the agreement may not be considered final as last minute hurdles could affect the deal.
Last July, Pfizer has put its animal health and nutrition businesses for sale as a part of its strategy to focus more on drug development, after losing patent protection for cholesterol drug Lipitor, which affected its net income.
The infant nutrition business, which became a part o